Tianjin Lisheng Pharmaceutical Co., Ltd.
2026 First Independent Directors' Special Meeting Review Opinions
In accordance with the "Administrative Measures for Independent Directors of Listed Companies," "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guide No. 1 - Normative Operation of Main Board Listed Companies," and other relevant laws, regulations, and the "Articles of Association," Tianjin Lisheng Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held its 2026 First Independent Directors' Special Meeting on March 24, 2025. Three independent directors were scheduled to attend, and three actually attended. All independent directors, based on an objective and fair stance, have reviewed and issued their opinions on the matters deliberated at the Fourth Meeting of the Eighth Board of Directors as follows:
I. Special Statement on the Company's Cumulative and Current External Guarantees and Fund Occupation
In accordance with relevant regulations, we have diligently reviewed the Company's external guarantee situation for 2025 and the situation of fund occupation by the controlling shareholder and other related parties, and hereby express our opinions as follows:
-
During the reporting period, there were no instances of the controlling shareholder or other related parties occupying the listed company's funds.
-
As of December 31, 2025, the Company had not provided guarantees for shareholders, shareholders' controlling subsidiaries, shareholders' affiliated enterprises, other related parties in which the Company holds less than 50% equity, or any non-legal entities or individuals.
-
At the end of the reporting period, the Company provided guarantees to its wholly-owned subsidiaries, Shenghua Pharmaceutical and Central Pharmaceutical, with an actual guarantee amount of RMB 90 million.
II. Self-Evaluation Report on the Company's Internal Control for 2025
In accordance with the provisions of relevant laws and regulations such as the "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guide No. 1 - Normative Operation of Main Board Listed Companies," after carefully reading the report and communicating with the Company's management and relevant departments, and reviewing the Company's management system, we believe that: